Seaport Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops novel medicines for neuropsychiatric disorders. The company's core technology is the Glyph platform, which is designed to deliver small molecule drugs through the lymphatic system, thereby enhancing oral bioavailability and minimizing hepatotoxicity. Seaport's lead clinical candidate, GlyphAllo (SPT-300), is an oral prodrug of allopregnanolone being evaluated for the treatment of major depressive disorder. Another key pipeline asset, GlyphAgo (SPT-320), is a prodrug of agomelatine targeted at generalized anxiety disorder. Founded in 2024 as a spin-out from PureTech Health, the company aims to overcome the historical limitations of clinically validated mechanisms in neuropsychiatry. Seaport Therapeutics is headquartered in Boston, Massachusetts.
